Effectiveness of Co-Testing in Cervical Cancer Screening Program in Macau SAR
- 1 Centro Hospitalar Conde de São Januário, Macau SAR, China
- 2 Centro Hospitalar Conde de São Januário, Macau SAR, China
Abstract
Background: Cervical cancer remains a significant public health concern in Macau SAR despite the implementation of a cervical cancer screening program and HPV vaccination. To improve early detection, Macau SAR introduced HPV DNA testing alongside cytology (co-testing) as the primary screening method in 2019. This study evaluates the effectiveness of co-testing in identifying cervical precancerous lesions (CIN2+) compared to cytology alone. Methods: We conducted a retrospective analysis of women aged 30 - 65 years who participated in the routine cervical cancer screening program in Macau SAR Primary Healthcare Centers from 2019 to 2022. Data from over 70,000 women were analyzed, comparing the detection rates of CIN2+ through co-testing and cytology alone. Women with abnormal cytology or positive HPV results were referred for colposcopy. Results: The introduction of co-testing led to a significant increase in the detection of CIN2+, particularly in women with atypical squamous cells of undetermined significance (ASCUS) or negative for intraepithelial lesion or malignancy (NILM) cytology results. Between 2019 and 2022, the percentage of women with ASCUS/NILM and any high-risk HPV (hrHPV) positive who were diagnosed with CIN2+ after colposcopy were 24%, 13%, 10% and 7.5% respectively. This highlights the ability of co-testing to identify high-risk individuals who would have been missed by cytology alone. Discussion: Our findings demonstrate the effectiveness of co-testing in improving the sensitivity of cervical cancer screening in Macau SAR. The inclusion of HPV DNA testing allows for better risk stratification of women with ASCUS/NILM cytology, leading to more targeted referrals for colposcopy and timely detection of precancerous lesions. The initial high positive rate in 2019 (24%) might be attributed to the small sample size and potentially reflects a backlog of undiagnosed cases prior to co-testing implementation. Conclusion: The implementation of co-testing in Macau SAR’s cervical cancer screening program significantly improves the early detection of precancerous lesions, particularly in women with ambiguous cytology results. This proactive approach contributes to reducing cervical cancer morbidity and mortality and improving women’s health outcomes in Macau SAR.
- Sung, H., Ferlay, J., Siegel, R.L., Laversanne, M., Soerjomataram, I., Jemal, A., et al . (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA : A Cancer Journal for Clinicians , 71, 209-249. https://doi.org/10.3322/caac.21660
- Cui, M., Chan, N., Liu, M., Thai, K., Malaczynska, J., Singh, I., et al . (2014) Clinical Performance of Roche Cobas 4800 HPV Test. Journal of Clinical Microbiology , 52, 2210-2211. https://doi.org/10.1128/jcm.00883-14
- Liu, S.S., Chan, K.K.L., Wei, T.N., Tse, K.Y., Ngu, S.F., Chu, M.M.Y., et al . (2022) Clinical Performance of the Roche Cobas 4800 HPV Test for Primary Cervical Cancer Screening in a Chinese Population. PLOS ONE , 17, e0272721. https://doi.org/10.1371/journal.pone.0272721
- Abulafia, O., Pezzullo, J.C. and Sherer, D.M. (2003) Performance of Thinprep Liquid-Based Cervical Cytology in Comparison with Conventionally Prepared Papanicolaou Smears: A Quantitative Survey. Gynecologic Oncology , 90, 137-144. https://doi.org/10.1016/s0090-8258(03)00176-8
- Taskforce for Annual Report of Macau Cancer Registry (2008-2018) Macao SAR Cancer Registration Annual Report, from 2008 to 2018. https://ssm.gov.mo/portal/content/ch/2234/stat.aspx
- Arbyn, M., Sasieni, P., Meijer, C.J.L.M., Clavel, C., Koliopoulos, G. and Dillner, J. (2006) Chapter 9: Clinical Applications of HPV Testing: A Summary of Meta-Analyses. Vaccine , 24, S78-S89. https://doi.org/10.1016/j.vaccine.2006.05.117
- Katki, H.A., Schiffman, M., Castle, P.E., Fetterman, B., Poitras, N.E., Lorey, T., et al . (2013) Five-Year Risks of CIN 2+ and CIN 3+ among Women with HPV-Positive and HPV-Negative LSIL Pap Results. Journal of Lower Genital Tract Disease , 17, S43-S49. https://doi.org/10.1097/lgt.0b013e3182854269
- The ASCUS-LSIL Triage Study (ALTS) Group (2003) Results of a Randomized Trial on the Management of Cytology Interpretations of Atypical Squamous Cells of Undetermined Significance. American Journal of Obstetrics and Gynecology , 188, 1383-1392.
- Gage, J.C., Hanson, V.W., Abbey, K., Dippery, S., Gardner, S., Kubota, J., et al . (2006) Number of Cervical Biopsies and Sensitivity of Colposcopy. Obstetrics & Gynecology , 108, 264-272. https://doi.org/10.1097/01.aog.0000220505.18525.85
- Moarcăs, M., Georgescu, I.C., Brătilă, E., Badea, M. and Cîrstoiu, M. (2014) Clinical Significance of HPV-DNA Testing for Precancerous Cervical Lesions. Journal of Medicine and Life , 7, 37-39.